Analysts Set Vor Biopharma Inc. (NASDAQ:VOR) Price Target at $73.17

by · The Cerbat Gem

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) has been given an average rating of “Hold” by the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $73.1667.

A number of equities research analysts recently weighed in on the company. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and increased their price target for the company from $20.00 to $64.00 in a research note on Wednesday, October 15th. Baird R W raised shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Zacks Research upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Wedbush initiated coverage on shares of Vor Biopharma in a research report on Tuesday, November 25th. They set a “neutral” rating for the company.

Read Our Latest Stock Analysis on Vor Biopharma

Vor Biopharma Trading Down 2.1%

Shares of VOR stock opened at $8.33 on Tuesday. The company has a fifty day moving average price of $21.90. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The firm has a market capitalization of $86.72 million, a PE ratio of -0.02 and a beta of 2.08.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the transaction, the insider owned 1,167,109 shares in the company, valued at $35,071,625.45. This trade represents a 0.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the firm’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $25.12, for a total value of $617,424.48. Following the completion of the transaction, the director owned 779,652 shares in the company, valued at $19,584,858.24. The trade was a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 2,256,863 shares of company stock valued at $55,056,369. 0.45% of the stock is currently owned by company insiders.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the company. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma in the first quarter valued at approximately $100,000. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. Fcpm Iii Services B.V. acquired a new position in shares of Vor Biopharma during the 3rd quarter worth $18,496,000. Jane Street Group LLC bought a new stake in shares of Vor Biopharma during the 1st quarter worth $140,000. Finally, XTX Topco Ltd bought a new position in Vor Biopharma in the second quarter valued at about $66,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

(Get Free Report)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

Featured Stories